BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Alternext US:RGN) announced today that an oral presentation entitled “The Use of Thymosin Beta 4 to Promote Healing of Neurotrophic Corneal Ulcers” will be presented at the 2009 Association for Research in Vision and Ophthalmology (ARVO) on Tuesday, May 5, at 3:45 p.m. ET in Ft. Lauderdale, Florida. The presentation will report on the healing effects of RGN-259 eye drops in patients with non-healing corneal ulcers. Dr. Gabriel Sosne, Associate Professor of Ophthalmology at Wayne State University School of Medicine and a member of RegeneRx’s Medical and Scientific Advisory Board will be presenting the clinical data.
